Articles from Basilea Pharmaceutica International Ltd, Allschwil

Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · April 9, 2026

Basilea announces start of first‑in‑human study of novel antibiotic BAL2420

Allschwil, Switzerland, March 23, 2026

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · March 23, 2026

Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · February 25, 2026

Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · February 17, 2026

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, February 09, 2026

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · February 9, 2026